Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis

BACKGROUND: Zoledronic acid is a potent inhibitor of osteoclast-mediated bone resorption and has been widely used in bone metastasis malignancies and postmenopausal osteoporosis as a preventive therapy against skeletal-related events. The purpose of this study was to evaluate the clinical outcome of...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Mingfeng, Fan, Weidong, Zhang, Xianquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874690/
https://www.ncbi.nlm.nih.gov/pubmed/24283946
http://dx.doi.org/10.1186/1756-8722-6-80

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874690/
https://www.ncbi.nlm.nih.gov/pubmed/24283946
http://dx.doi.org/10.1186/1756-8722-6-80

Ejemplares similares